Immunotherapies for Lung Cancer: Recent Approvals
This fact sheet discusses recent advances in immuno-oncology for advanced lung cancers.
Lung Cancer
Tepotinib Validated for NSCLC With MET Exon 14-Skipping Mutation
A small percentage of patients with NSCLC could stand to benefit from tepotinib.
Change in Longitudinal Level of EGFR ctDNA May Predict Benefit of Savolitinib Plus Osimertinib in NSCLC Patient Subset
This post-hoc analysis compared efficacy of savolitinib plus osimertinib and change in EGFR ctDNA in advanced EGFR-mutant NSCLC characterized by MET amplification.
Definition of Hyperprogressive Disease in NSCLC Varies Widely, Study Finds
The definition of hyperprogressive disease (HPD) in advanced non–small cell lung cancer was found to vary widely, yielding “highly variable” rates of HPD.
Zepzelca Approved for Metastatic Small Cell Lung Cancer
The FDA has approved Zepzelca™ (lurbinectedin; Jazz Pharmaceuticals) for the treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.
Prior PD-1 Blockade Did Not Appear to Influence the Severity of COVID-19 in Patients With Lung Cancer
There have been some concerns that the immunomodulatory effect of PD-1 blockade may influence the response of patients with cancer to COVID-19.
KEYNOTE-604: Pembrolizumab Missed OS Endpoint in First-Line SCLC, but Appeared to Prolong Survival in Some Patients
The drug did, however, significantly improve progression-free survival.
Researchers Present Evidence in Support of Broad Next-Generation Sequencing in Advanced Nonsquamous NSCLC
Though they are costly, broad genetic assays that look for many gene mutations at once may confer more value overall than a one-off testing approach for patients with nsNSCLC.
Nivolumab Plus Ipilimumab Yields Long-Term Responses in Advanced NSCLC
Overall, grade 3 to 4 AEs were noted in 33% of patients receiving the immunotherapy combination vs 36% of patients receiving chemotherapy.
Bintrafusp Alfa: Durable Responses Noted in NSCLC
In the 3 ongoing responses, all had PD-L1–positive disease.
-
Loading...
-
Loading...
Next post in ASCO 2020 Lung Cancer In-Depth
